Some of the most innovative and efficacious new products being launched are cell and gene therapies. However, healthcare systems globally are not set up to properly capture the value of these therapies given most are single-use, and have high upfront cost, uncertain durability of effect, and are not proven consistently safe.

Key objectives:

• Review what makes cell and gene therapies unique, and why that creates market access challenges, but also opportunities
• Discuss how innovative contracting is helping to overcome some of the global market access challenges, but new approaches may be needed for reimbursement
• Share perspectives on what the future market access environment will be for cell and gene therapies

Speakers

Rob Glik
VP and GM, Value & Access Strategy Consulting, IQVIA

Justin DiSanto
Principal, Value & Access Strategy Consulting, IQVIA